Actavis

The US Food and Drug Administration (FDA) have ruled against Shire in a clash surrounding generic copies of their ADHD medication, Adderall XR, by approving a cheap version of the drug from Watson’s Actavis division. The verdict is a setback to Shire’s near-term earnings and shares, with the drug maker’s shares falling 12.4% to £17.23